Health eHeart BioBank

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06976502
Status
Enrolling By Invitation

Conditions

  • Cardiac Diseases
  • Cardiovascular Diseases
  • Heart Diseases
  • Vascular Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Blood Draw — PROCEDURE
    Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.
  • Tissue Collection — PROCEDURE
    If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.
  • DNA Collection — PROCEDURE
    Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.
  • Medical Chart Review — OTHER
    Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Study Details

The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.

Key Dates

Start date
Apr 1, 2025
Status verified
Jun 2025
Primary completion
Dec 31, 2035
Completion
Dec 31, 2035

Study Design

Enrollment
500,000 participants (estimated)

Arms

  • Arm: Participants with a History of Cardiovascular Disease
  • Arm: Participants with a Family History of Cardiovascular Disease
  • Arm: Healthy Controls

Primary Outcome Measure

Establish and Maintain a Centralized Biorepository [ Time Frame: Up to 10 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94158-

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies